Pluri Completes First Phase of Resbiomed Program for Placenta-Derived Biomaterials.

Pluri, Inc. has completed the first phase of its program with Resbiomed Technologies OOD to develop extracellular-matrix-based biomaterials and biologics for regenerative medicine. The program aims to enhance, standardize, and enable scalable production of placenta-derived biomaterials containing naturally occurring human collagen. PluriCDMO, the company's contract development and manufacturing division, is applying its proprietary placenta-derived processing and bioprocessing capabilities to support Resbiomed. The collaboration aims to expand access to regenerative medicine, advanced wound care, medical devices, and other applications.